- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00820508
Safety and Tolerability of CHR-2845 to Treat Haematological Diseases or Lymphoid Malignancies (CHR-2845-001)
November 25, 2011 updated by: Chroma Therapeutics
A Phase I Study to Evaluate the Safety and Tolerability of the Histone Deacetylase Inhibitor, CHR-2845, in Patients With Advanced or Treatment Refractory Haematological Diseases or Lymphoid Malignancies
The purpose of this study is to determine whether the histone deacetylase inhibitor CHR-2845 is tolerated in patients with haematological diseases and lymphoid malignancies.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
CHR-2845 is a novel type of histone deacetylase inhibitor (HDACi) for use in cancer that, in addition to having broad ranging anti-proliferative activity against transformed cells, is designed to have an increased therapeutic window against diseases which involve cells of the monocyte-macrophage lineage.
There are several HDACi's in clinical development and one, SAHA (Vorinostat, Zolinza®), has recently been approved for use in the treatment of cutaneous T-cell lymphoma.
CHR-2845 is a cell-permeant ester that is metabolised to give an active acid, CHR-2847, which selectively accumulates in monocytes and macrophages.
This results in a 20-100 fold increase in anti-proliferative potency of CHR-2845 for monocytic over non-monocytic tumour cells.
This selectivity should lead to an increased therapeutic window in haematological malignancies involving cells of the monocyte lineage (AML M4, AML M5 and CMML).
In addition, there is increasing evidence that monocytes and macrophages associated with some haematological tumours (tumour-associated macrophages (TAMs)) are involved in supporting the growth and spread of the tumour.
This clinical trial will focus on haematological and lymphoid malignancies with the intention of evaluating the safety and tolerability of CHR-2845.
Additionally it will compare response in patients where monocytes/macrophages are important disease drivers, with the response in other patients.
This will allow an early determination of the potential improvement in therapeutic window afforded by the monocyte/macrophage directed HDACi activity.
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Antwerp, Belgium, 2060
- ZNA Stuivenberg
-
-
-
-
-
Marseille, France
- Institut Paoli-Calmettes
-
-
-
-
-
Amsterdam, Netherlands, 1007 MB
- VU University Medical Center
-
Rotterdam, Netherlands, 3015 CE
- Erasmus University Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Signed, informed consent
- Confirmed malignant haematological disease or lymphoid malignancy refractory to standard therapy or for which no standard therapy exists, including acute leukemias, MDS, CML, CLL, CMML, multiple myeloma and Non-Hodgkin's Lymphomas/Hodgkin's disease
- Patients shall have recovered from all acute adverse effects of prior therapies, with the exception of alopecia and grade 1 neuropathy where recovery is not required
Adequate bone marrow, hepatic and renal function including the following:
- Patients with high blast counts can be included if they can be controlled by the use of hydroxyurea (500 mg -3,000 mg daily).
- Total bilirubin ≤ 1.5 x upper normal limit, excluding cases where elevated bilirubin can be attributed to Gilbert's Syndrome
- AST (SGOT), ALT (SGPT) ≤ 2.5 x upper normal limit
- Creatinine ≤ 1.5 x upper normal limit
- Age ≥ 18 years
- Performance status (PS) ≤ 2 - Eastern Cooperative Oncology Group (ECOG) scale
- Estimated life expectancy greater than 3 months
- Female patients with reproductive potential must have a negative serum pregnancy test within 7 days prior to start of trial. Both women and men must agree to use a medically acceptable method of contraception throughout the treatment period and for 3 months after discontinuation of treatment.
Exclusion Criteria:
- Patients receiving anti-cancer therapy or use of other investigational agents within 21 days prior to trial entry (or a longer period depending on the defined characteristics of the agents used. Bisphosphonates for bone disease and corticosteroids are permitted provided the dose does not change during the trial. Patients must have recovered from all transient toxicity induced by prior therapy
- Patients with co-existing active infection, graft versus host disease or serious concurrent illness
- Patients who have failed to recover from or after a bone marrow transplantation or haematopoietic stem cell transplantation
- The following diseases are excluded: Burkitt's lymphoma, primary effusion lymphoma, precursor B-cell lymphoblastic lymphoma, symptomatic central nervous system (CNS) lymphoma, CML blast crisis
Patients with significant cardiovascular disease as defined by:
- history of congestive heart failure requiring therapy
- history of angina pectoris requiring treatment or myocardial infarction within 6 months prior to trial entry
- presence of severe valvular heart disease
- presence of an atrial or ventricular arrhythmia requiring treatment
- Left Ventricular Ejection Fraction (LVEF) below the normal range at the study centre
- Uncontrolled hypertension
- A history of abnormal QTc intervals or an average QTc interval at screening ≥450 msec
- Any medical or other condition that in the investigator's opinion renders the patient unsuitable for this study due to unacceptable risk
- Psychiatric disorders or altered mental status precluding understanding of the informed consent process and/or completion of the necessary studies
- Gastrointestinal disorders that may interfere with absorption of the study drug
- Patients with known brain tumours or metastases
- More than 6 prior chemotherapy regimens
- Patients requiring growth factor support (erythropoietin, Granulocyte/monocyte Colony Stimulating Factor (GM/CSF), etc)
- Patients requiring palliative radiotherapy within the last 4 weeks prior to study entry
- Uncontrolled hypercalcaemia (CTCAE v3 grade 2 or higher)
- Abnormal plasma potassium or magnesium levels (Common Terminology Criteria for Adverse Events (CTCAE) v3 grade 3 or greater) despite therapy
- Pregnant or breast-feeding women
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 1
Oral, once daily administration of CHR-2845 to determine safety and tolerability
|
Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the safety, tolerability, dose-limiting toxicities (DLT), maximum acceptable dose (MAD) and maximum tolerated dose (MTD)
Time Frame: 28 days
|
28 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine pharmacokinetic parameters of CHR-2845 and the active metabolite CHR-2847
Time Frame: days 1 and 28
|
days 1 and 28
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bob Löwenberg, M.D, Erasmus Medical Center
- Principal Investigator: Gert Ossenkoppele, M.D, Amsterdam Umc, Location Vumc
- Principal Investigator: Pierre Zachee, MD, ZNA Stuivenberg
- Principal Investigator: Norbert Vey, MD, Institut Paoli-Calmettes
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
December 1, 2008
Primary Completion (Actual)
July 1, 2011
Study Completion (Actual)
July 1, 2011
Study Registration Dates
First Submitted
January 9, 2009
First Submitted That Met QC Criteria
January 9, 2009
First Posted (Estimate)
January 12, 2009
Study Record Updates
Last Update Posted (Estimate)
November 28, 2011
Last Update Submitted That Met QC Criteria
November 25, 2011
Last Verified
November 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CHR-2845-001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoid Malignancies
-
Curon Biopharmaceutical (Australia) Co Pty LtdNovotech (Australia) Pty LimitedTerminatedRelapsed Lymphoid Malignancies | Refractory Lymphoid MalignanciesAustralia
-
Shanghai Jiao Tong University School of MedicineCompletedLymphoid MalignanciesChina
-
Human Genome Sciences Inc.TerminatedLymphoid MalignanciesUnited States, United Kingdom
-
Gilead SciencesTerminatedLymphoid MalignanciesNetherlands
-
Shanghai Escugen Biotechnology Co., LtdEscugen (Australia) Biotechnology Pty LtdNot yet recruitingB-cell Lymphoid Malignancies
-
M.D. Anderson Cancer CenterReata Pharmaceuticals, Inc.CompletedSolid Tumors | Lymphoid MalignanciesUnited States
-
Cristina GasparettoAgilent Technologies, Inc.Active, not recruitingLymphoid Malignancies | Myeloid MalignanciesUnited States
-
Shanghai Escugen Biotechnology Co., LtdRecruitingB-cell Lymphoid MalignanciesChina
-
OncoMed Pharmaceuticals, Inc.CompletedRelapsed or Refractory Lymphoid MalignanciesUnited States
-
Reata, a wholly owned subsidiary of BiogenCompletedAdvanced Solid Tumors | Lymphoid MalignanciesUnited States
Clinical Trials on CHR-2845
-
GlaxoSmithKlineTerminatedArthritis, RheumatoidUnited Kingdom
-
Rhode Island HospitalRecruitingPsychosis Nos/OtherUnited States
-
University of California, IrvineUniversity of Maryland, Baltimore CountyNot yet recruitingSuicide | Psychosis | Health Care Utilization | Family Members
-
Chroma TherapeuticsUnknownAcute Myeloid LeukemiaUnited States
-
Weill Medical College of Cornell UniversityCTI BioPharmaCompletedMyelodysplastic SyndromeUnited States
-
Chroma TherapeuticsCompletedAcute Myeloid Leukemia | Multiple Myeloma | Myelodysplastic SyndromeUnited Kingdom
-
Icahn School of Medicine at Mount SinaiNational Institute of Mental Health (NIMH)RecruitingClinical High Risk for Psychosis (CHR)United States
-
Chroma TherapeuticsInstitute of Cancer Research, United KingdomCompletedAdvanced Solid Tumors
-
Chroma TherapeuticsQuintiles, Inc.CompletedAcute Myeloid Leukemia | AMLUnited States, Canada, Netherlands
-
Chroma TherapeuticsCompleted